Omeros Grabs $3.1M

Luke Timmerman1/28/09

Omeros, the privately held Seattle-based drug developer, said today it received $3.1 million in equity financing and grants from The Stanley Medical Research Institute to continue animal testing of a treatment for schizophrenia. Omeros previously received $2.6 million from the institute when it reached an agreement to begin the schizophrenia work in December 2006. Earlier this month, Omeros received a $465,000 grant from the Michael J. Fox Foundation for Parkinson’s Research.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.